The FDA authorizes the first at-home HPV self-collection

Two different changes, two years apart

The phrase "self-collection" has covered two separate steps in the United States. It helps to keep them apart.

The first came on May 14, 2024. On that date the FDA signed off on self-collected vaginal samples for two HPV tests. One was Roche's cobas HPV test. The other was the BD Onclarity HPV Assay. The approval orders are on file as P190028/S009 and P160037/S017.

There was a catch. The sample still had to be collected in a health care setting. That could be a clinic, an urgent care, a pharmacy, or a mobile van. It could not be your bathroom.

The second step came a year later. In May 2025, Teal Health announced FDA approval of the Teal Wand. The ASCO Post reported it as the first at-home self-collection device for cervical cancer screening in the country.

How the at-home version works

The company describes it as a prescription device for people aged 25 to 65 who are at average risk. A clinician has to order it.

You collect a vaginal sample yourself and mail it to a lab. The lab runs the same Roche cobas HPV test used in clinics. A telehealth service handles the prescription and the results.

So the test is not new. The way the sample gets to the lab is.

Teal Health reported that its SELF-CERV study found self-collected samples performed the same as clinician-collected ones, detecting cervical precancer 96% of the time. That figure comes from the company's own account of the study. Independent, published data will matter as the device is used more widely.

What HPV screening is looking for

Nearly all cervical cancer starts with a lasting infection by a high-risk type of human papillomavirus, or HPV. HPV is a common virus passed on through sexual contact. Most infections clear on their own.

When one does not clear, it can slowly change cells on the cervix. Those changed cells are called cervical intraepithelial neoplasia, or CIN. CIN is not cancer. It is a precancer, and treating it stops cancer from forming.

That is why screening works so well here. It does not just find cancer early. It finds the step before cancer and removes it. Our overview of cervical cancer walks through how the cervix is examined and what the grades mean.

A positive result is a beginning, not an answer

An HPV test tells you whether a high-risk type is present. It does not tell you whether any cells have changed.

So a positive result leads to more steps. That usually means a Pap test on the same sample, and often colposcopy. In colposcopy a clinician looks at the cervix through a lighted magnifier and takes a small biopsy if anything looks off. NCI lists colposcopy, biopsy, and endocervical curettage among the standard follow-up steps.

None of that can be done at home. An at-home kit widens the front door. It does not replace the rest of the building.

When to get checked

The U.S. Preventive Services Task Force sets the routine schedule for people with a cervix:

• Ages 21 to 29: a Pap test every 3 years.
• Ages 30 to 65: a Pap test every 3 years, or a high-risk HPV test every 5 years, or both together every 5 years.
• Under 21: no screening.
• Over 65: no screening if past screening was adequate and risk is not raised.

Symptoms are a separate track. NCI notes that early cervical cancer often causes nothing you would notice. When signs do appear, they include vaginal bleeding, bleeding after sex, unusual discharge, pelvic pain, and pain during sex. Any of those deserve an appointment, whatever your screening schedule says.

Talk to a clinician sooner if you have HIV, take drugs that suppress the immune system, or were treated for a high-grade cervical lesion in the past.

What this does not mean

• It does not mean at-home collection replaces a pelvic exam, a Pap test, or colposcopy.
• It does not mean anyone can order a kit. These are prescription devices with a defined age range.
• It does not change how often you should be screened. The interval comes from your history, not from the collection method.
• It does not remove the value of the HPV vaccine, which prevents the infections screening looks for.
• Availability, insurance coverage, and the labeling of each test can shift. Check the current FDA record rather than a news date.

Screening has real trade-offs, including false alarms and procedures that turn out not to have been needed. Our page on the benefits and harms of screening sets those out plainly, and the wider screening overview shows how cervical screening compares with other programs.

The scale of the problem

The American Cancer Society projects about 13,490 new cervical cancer diagnoses in the United States in 2026, and about 4,200 deaths, a projection SEER republishes alongside its own measurements. Five-year relative survival across all stages was 68.8% for 2016 to 2022. About 41% of cases are found while still confined to the cervix.

Those are group figures drawn from past years of care. They describe a population, not a person, and they do not predict any individual outcome. The reason they matter here is simpler: NCI notes that most cervical cancer is diagnosed where screening is hard to reach. Anything that lowers that barrier is worth watching closely.

Sources

• FDA premarket approval record P190028, Roche cobas HPV (openFDA device API)
• FDA premarket approval record P160037, BD Onclarity HPV Assay (openFDA device API)
• The ASCO Post: FDA Approves At-Home Self-Collection Device for Cervical Cancer Screening
• NCI PDQ: Cervical Cancer Treatment (Health Professional Version)
• USPSTF: Cervical Cancer Screening
• SEER Cancer Stat Facts: Cervical Cancer

How this page was made

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

Cancer Explained is published by the National Cancer Information Foundation. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.